Analysed SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) News Sources
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
13-05-2026
yahoo.com
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
14-05-2026
yahoo.com
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
15-05-2026
yahoo.com
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
18-05-2026
yahoo.com
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
29-07-2026
yahoo.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
04-08-2026
yahoo.com
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14-08-2026
yahoo.com
What is the current price of SILEXION THERAPEUTICS CORP (SLXN:NASDAQ)?
The current price of SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) is $0.3573.
SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) absolute price change since previous trading day?
The absolute price change of SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) since the previous trading day is $-0.0652.
SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) percentage price change since previous trading day?
The percentage price change of SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) since the previous trading day is -15.432%.
What is the most recent average sentiment score for SILEXION THERAPEUTICS CORP (SLXN:NASDAQ)?
The most recent average sentiment score for SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for SILEXION THERAPEUTICS CORP (SLXN:NASDAQ)?
The most recent sentiment for SILEXION THERAPEUTICS CORP (SLXN:NASDAQ) is .
SEC-8K** Filing Available For SILEXION THERAPEUTICS CORP (SLXN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.